ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2014
Efficacy of liraglutide in a real-life cohort.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Article
- Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia.Journal of clinical medicine · 2019Article
- A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Article
- Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Article
- Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017Article
- Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017Article
- Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017Article
- Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2016Review
- Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2015Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn the Liraglutide Effect and Action in Diabetes (LEAD) randomized clinical trials (RCTs) assessing liraglutide in type 2 diabetes mellitus (T2DM), glycated hemoglobin (A1c) was reduced by 7-16 mmol/mol and weight by up to 3.4 kg. As real-life efficacy data on liraglutide is limited, the authors assessed clinical effects in a real-life cohort.
methodsIn this retrospective analysis from the Israeli Health Maintenance Organization Maccabi, of patients with T2DM, treated with liraglutide ≥6 months during 2011-2012, evaluations were performed at baseline and 6 months.
resultsInsulin-naïve patients (n = 1,101) treated with liraglutide with at least one A1c or weight measurement were identified. In 933 patients with an additional A1c value after 6 months, A1c decreased by 9 mmol/mol (p < 0.0001, 95% CI 7-11) from 72 mmol/mol. In patients receiving >2 oral antidiabetic drugs (OADs) prior to liraglutide treatment (80.7% patients), A1c decreased by 7 mmol/mol, and in those receiving ≤2 OADs, by 12 mmol/mol. In 453 patients with baseline data available, weight decreased by 2.55 kg (p < 0.0001); 173 patients (38.18%) achieved ≥1% A1c reduction. Furthermore, 91 patients (20.1%) achieved National Institute for Health and Care Excellence (NICE) criteria (decreased A1c ≥1%; weight ≥3%). Weight reduction was marginally correlated with A1c reduction.
conclusionsEvidence from real-life use of liraglutide demonstrated clinical effects similar to those demonstrated in RCTs.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.